Share
 
Title
Code
Session Type
Format
ROOM/CHANNEL
Date Time
Co-Chairs
Organizer

Aim Explore barriers and facilitators to community's meaningful engagement and participation in industry-led HIV cure research to ensure acceptability, scalability, and cost effectiveness of HIV cure research interventions. Description Although antiretroviral therapy (ART) can efficiently control HIV infection and improve the lives of people living with HIV, treatment requires life-long adherence, which is challenging for many due to a host of factors. An HIV cure could overcome the limitations of ART, reduce new HIV transmissions, stigma and discrimination, and provide a sustainable financial solution for epidemic control. Efforts to coordinate HIV cure research engagement and advocacy have emerged through formal partnerships between academia and industry. Engaging community in this effort remains an imperative, especially in sub-Saharan Africa which bears the burden of HIV infection. Increasing knowledge dissemination, building capacity for advocacy, and increasing involvement of end-users into the strategy and design of cure research are key to ensure acceptability, scalability, and cost effectiveness of HIV cure research interventions. This satellite will discuss how best to engage and involve communities of people living with HIV in end-to-end product development and in particular clinical research in Africa.

14:45
1 min
Welcome
Alan LANDAY, Rush University Medical Center, United States
14:46
5 min
Introduction
Jan VAN LUNZEN, Germany
14:51
10 min
Overview of ongoing cure research strategy and why doing research in Africa
Sharon LEWIN, The University of Melbourne, Australia
15:01
10 min
Strengthening industry-community engagement in clinical research: Lessons learnt from HIV Prevention trials
Nandi LUTHULI, AVAC, United States
15:11
10 min
How clinical research is involving communities
Thumbi NDUNG'U, Africa Health Research Institute, South Africa
15:21
10 min
Industry needs and current approach to community engagement
Devi SENGUPTA, Gilead Sciences, United States
15:31
35 min
Panel discussion and Q&A
Bonnie HOWELL, Merck, United States
Izukanji SIKAZWE, Centre for Infectious Disease Research in Zambia, Zambia
Thumbi NDUNG'U, Africa Health Research Institute, University of KwaZulu-Natal, South Africa
Jan VAN LUNZEN, Germany
Josephine NABUKENYA, Uganda
Marina CASKEY, The Rockefeller University, United States
Jeffrey SAFRIT, ImmunityBio, Inc., United States
Alan LANDAY, Rush University Medical Center, United States
Timothy HENRICH, UCSF, United States
16:06
5 min
Closing remarks and co-chair handover
Bonnie HOWELL, Merck, United States
Jan VAN LUNZEN, Germany
Alan LANDAY, Rush University Medical Center, United States
Timothy HENRICH, UCSF, United States